Browsing Tag
doxorubicin
3 posts
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful…
Avacta Group progresses to final cohort in Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leader in the life sciences sector specializing in innovative oncology drugs and…